Columnist Juliet Taylor explains how her goals and priorities dramatically shifted while living with her late husband's ALS.

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP) for people with ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ALS, she says.

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial ...